Yüksel Ürün(@DrYukselUrun) 's Twitter Profileg
Yüksel Ürün

@DrYukselUrun

Prof. Medical Oncologist 🔬 @AnkaraUni 🎓 Advocate for #Diversity & #Equity 🌟 Genitourinary Cancer I 2023-2024 @ASCO Leadership Development Program

ID:2798480350

linkhttps://yukselurun.com/ calendar_today01-10-2014 17:42:21

10,4K Tweet

6,5K Takipçi

575 Takip Edilen

Follow People
M. Bolton(@5_utr) 's Twitter Profile Photo

This reminds me of the NEJM work randomizing early palliative care vs continued systemic therapy, palliative care conferred survival benefit nejm.org/doi/full/10.10…

This reminds me of the @NEJM work randomizing early palliative care vs continued systemic therapy, palliative care conferred survival benefit nejm.org/doi/full/10.10…
account_circle
Christian Rolfo(@ChristianRolfo) 's Twitter Profile Photo

Very proud of the great Meeting on hosted in the magical city of Granada Spain 🇪🇸. M JOSE SERRANO (LB&Cancer Interception group) our International Society of Liquid Biopsy Vice president is organizing with Massimo Cristofanilli, MD, FACP our past-president. Great agenda and faculty! Don’t miss it!

account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

Ketojenik Diyetler Uzun Vadeli Sağlık Sorunlarına Yol Açabilir!

⭕️Science Advances'de yayınlanan yeni araştırmaya göre, ketojenik diyetler (KD) kilo kaybı ve belirli sağlık koşullarının tedavisi için popülerdir, ancak her zaman faydalı olmayabilirler.
⭕️Araştırma, ketojenik

Ketojenik Diyetler Uzun Vadeli Sağlık Sorunlarına Yol Açabilir! ⭕️Science Advances'de yayınlanan yeni araştırmaya göre, ketojenik diyetler (KD) kilo kaybı ve belirli sağlık koşullarının tedavisi için popülerdir, ancak her zaman faydalı olmayabilirler. ⭕️Araştırma, ketojenik
account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

Does oncologic treatment for very advanced disease improve survival?
1⃣The study analyzed 78,446 adult patients with six common metastatic solid tumors. It found no significant survival benefit for patients receiving more systemic therapy for very advanced cancer.
2⃣There was no

Does oncologic treatment for very advanced disease improve survival? 1⃣The study analyzed 78,446 adult patients with six common metastatic solid tumors. It found no significant survival benefit for patients receiving more systemic therapy for very advanced cancer. 2⃣There was no
account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

Ketojenik Diyetler Uzun Vadeli Sağlık Sorunlarına Yol Açabilir!

⭕️Science Advances'de yayınlanan yeni araştırmaya göre, ketojenik diyetler (KD) kilo kaybı ve belirli sağlık koşullarının tedavisi için popülerdir, ancak her zaman faydalı olmayabilirler.
⭕️Araştırma, ketojenik

Ketojenik Diyetler Uzun Vadeli Sağlık Sorunlarına Yol Açabilir! ⭕️Science Advances'de yayınlanan yeni araştırmaya göre, ketojenik diyetler (KD) kilo kaybı ve belirli sağlık koşullarının tedavisi için popülerdir, ancak her zaman faydalı olmayabilirler. ⭕️Araştırma, ketojenik
account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

Next-generation sequencing is key for managing NSCLC, enabling comprehensive molecular profiling for targeted therapies. Best practice recommendations for reporting ensure clear, actionable results.
Umberto Malapelle Christian Rolfo

Next-generation sequencing is key for managing NSCLC, enabling comprehensive molecular profiling for targeted therapies. Best practice recommendations for reporting ensure clear, actionable results. #LungCancer #NGS #Oncology #PrecisionMedicine @UmbertoMalapel1 @ChristianRolfo
account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

Perioperative nivolumab for resectable NSCLC improves 18-month event-free survival to 70.2% vs. 50.0% with chemo and achieves a 25.3% pathological complete response rate. NEJM OncoAlert

Perioperative nivolumab for resectable NSCLC improves 18-month event-free survival to 70.2% vs. 50.0% with chemo and achieves a 25.3% pathological complete response rate. #LungCancer #Immunotherapy #NSCLC @NEJM @OncoAlert
account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

Top Advances of the Year: Perioperative Therapy for Lung Cancer

⭕️In 2023, perioperative immune checkpoint inhibitors (ICIs) became a game-changer for early-stage non-small cell lung cancer (NSCLC).
⭕️ Despite these advances, optimizing patient selection and biomarker use

Top Advances of the Year: Perioperative Therapy for Lung Cancer ⭕️In 2023, perioperative immune checkpoint inhibitors (ICIs) became a game-changer for early-stage non-small cell lung cancer (NSCLC). ⭕️ Despite these advances, optimizing patient selection and biomarker use
account_circle
International Society of Liquid Biopsy(@isliquidbiopsy) 's Twitter Profile Photo

The ISLB president presenting an overview of the role of extracellular vesicles (EV) and circulating tumor cells in diagnosis/response monitoring in patients with NSCLC at NIH Liquid Biopsy Conference in Bethesda, MD
The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai

The ISLB president presenting an overview of the role of extracellular vesicles (EV) and circulating tumor cells in diagnosis/response monitoring in patients with NSCLC at @NIH Liquid Biopsy Conference in Bethesda, MD @TischCancer @IcahnMountSinai
account_circle
Niklas Klümper(@niklas_kluemper) 's Twitter Profile Photo

Happy to share our editorial on biomarkers to predict immunotherapy response for CRPC European Urology

➡️ MSI-H, dMMR, and TMB-H are promising biomarkers to predict ICI respone in CRPC
➡️ they occur very rarely in CRPC (2–5%), with frequent co-occurence ! (>90%)
➡️ICI can be

account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

Long-term weight loss effects of semaglutide

🔴SELECT trial show semaglutide leads to sustained weight loss in adults with obesity without diabetes.
🔴Significant reductions in weight, waist circumference, and fewer serious adverse events compared to placebo.

Long-term weight loss effects of semaglutide 🔴SELECT trial show semaglutide leads to sustained weight loss in adults with obesity without diabetes. 🔴Significant reductions in weight, waist circumference, and fewer serious adverse events compared to placebo.
account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

Revolutionizing Cancer Care

🩸🧬🔎A new machine learning-based immune profiling platform uses blood tests to identify five unique immunotypes in cancer patients.
⭕️This simple test can predict treatment responses, personalizing cancer therapy and improving outcomes.

Revolutionizing Cancer Care 🩸🧬🔎A new machine learning-based immune profiling platform uses blood tests to identify five unique immunotypes in cancer patients. ⭕️This simple test can predict treatment responses, personalizing cancer therapy and improving outcomes.
account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

A study from 🇸🇪 on over 350,000 men:
⭕️ α1-adrenoceptor antagonists do not increase mortality from prostate cancer nor the risk of high-grade prostate cancer.
⭕️However, these drugs are linked to a slight increase in overall prostate cancer incidence, especially lower-grade

A study from 🇸🇪 on over 350,000 men: ⭕️ α1-adrenoceptor antagonists do not increase mortality from prostate cancer nor the risk of high-grade prostate cancer. ⭕️However, these drugs are linked to a slight increase in overall prostate cancer incidence, especially lower-grade
account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

“Yemek yemek üstüne ne düşünürsünüz bilmem
Ama kahvaltının mutlulukla bir ilgisi olmalı” diye boşuna dememiş C. Süreya

account_circle